Treatment of metastatic breast cancer: a historical perspective

被引：0
作者：
C. C. Zielinski
机构：
[1] Medical University of Vienna,Clinical Division of Oncology, Department of Medicine I
来源：
memo - Magazine of European Medical Oncology | 2008年 / 1卷 / 4期
关键词：
Anti-angiogenic agents; Bevacizumab; Biological agents; Hormonal therapies; Metastatic breast cancer;
D O I：
10.1007/s12254-008-0066-6
中图分类号：
学科分类号：
摘要：
Metastatic breast cancer is incurable and treatment decisions are complex. Despite the range of therapeutic agents available and the use of different approaches with these agents, an efficacy plateau had been reached. The development of novel therapies based on a greater understanding of the aetiology of breast cancer has begun to produce unprecedented increases in efficacy. This paper reviews the latest advances in the treatment of metastatic breast cancer, including the established aromatase inhibitors and human epidermal growth factor receptor 2-targeted therapies. The recent introduction of anti-angiogenic therapies, such as bevacizumab, may have even greater impact due to their potential to benefit all breast cancer patients.
引用
收藏
页码：227 / 234
页数：7
相关论文
共 170 条
[21]  
Fritz P(2001)Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group J Clin Oncol 19 2232-473
[22]  
Gibson LJ(2002)Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812-238
[23]  
Dawson CK(2001)Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group J Clin Oncol 19 2213-967
[24]  
Lawrence DH(2003)Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexatemitomycin C (MMM-G) in metastatic breast carcinoma J Chemother 15 184-182
[25]  
Bliss JM(1993)Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration J Clin Oncol 11 467-2904
[26]  
Pietras RJ(2002)Phase III study of docetaxel 100 versus 75 versus 60 mg/m Breast Cancer Res Treat 76 S88-2648
[27]  
Arboleda J(2006) as second line chemotherapy in advanced breast cancer Ann Oncol 17 232-726
[28]  
Reese DM(2006)Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects Anticancer Drugs 17 961-749
[29]  
Newby JC(2007)Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer J Clin Oncol 25 33s-2251
[30]  
Johnston SR(1987)Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T Science 235 177-216
12345678910